GSK migraine combo is Trexima
GlaxoSmithKline/Pozen's acute migraine therapy combining Imitrex and naproxen will be marketed under the proposed brand name Trexima. Companies have commenced Phase III studies on the sumatriptan/naproxen fixed-dose combination and expect to submit an NDA in the second half of 2005. GSK and Pozen signed the development agreement in June 2003...
You may also be interested in...
FDA's "not approvable" letter for Pozen's naproxen/ metoclopramide migraine combination MT-100 may prompt the company to revisit the Phase III trial design for an Imitrex combo under development with GlaxoSmithKline
Cosmetics Europe Talks Microplastic: ECHA Frustrations, ‘Value Judgments’ And International Trade Uncertainty
The European Chemicals Agency's microplastic restriction proposal received committee backing in 2020 without changes sought by the cosmetics industry, which faces €15bn in projected costs and scarce alternatives at present. It may come down to EU Member States to decide whether the ECHA restriction proposal is proportionate in balancing environmental goals and socio-economic impacts.
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.